Individual generic drug information

sucralfate

Reference monograph

Part of registered formulation

SUCRALFATE + OXETACAINE

Reference record: Sucralfate
Source: BNF 80 (2020–2021)
Printed source pages: 100, 101
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Sucralfate only.

Indications And Dose

Benign gastric ulceration | Benign duodenal ulceration ▶BY MOUTH ▶Child 15–17 years: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day ▶Adult: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day Chronic gastritis ▶BY MOUTH ▶Adult: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day Prophylaxis of stress ulceration in child under intensive care ▶BY MOUTH ▶Child 15–17 years: 1 g 6 times a day; maximum 8 g per day Prophylaxis of stress ulceration ▶BY MOUTH ▶Adult: 1 g 6 times a day; maximum 8 g per day l UNLICENSED USE ▶In children Tablets not licensed for prophylaxis of stress ulceration.

Source page 100

Cautions

Patients under intensive care (Important: reports of bezoar formation) CAUTIONS, FURTHER INFORMATION ▶Bezoar formation Following reports of bezoar formation associated with sucralfate, caution is advised in seriously ill patients, especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying. Signs and symptoms of gastric cancer (in adults) CAUTIONS, FURTHER INFORMATION ▶Gastric cancer ▶In adults H2-receptor antagonists might mask symptoms of gastric cancer; particular care is required in patients presenting with ‘alarm features’ in such cases gastric malignancy should be ruled out before treatment.

Source page 100

Prescribing And Dispensing Information

Flavours of oral liquid formulations may include aniseed and caramel.

Source page 100

Safety

Extracted information for Sucralfate only.

Interactions

→Appendix 1: sucralfate

Source page 100

Side Effects

▶Common or very common Constipation ▶Uncommon Dry mouth. nausea ▶Rare or very rare Bezoar. rash ▶Frequency not known Back pain. bone disorders. diarrhoea . dizziness. drowsiness. encephalopathy. ﬂatulence. headache. vertigo ▶Common or very common Constipation. diarrhoea. dizziness. fatigue. headache. myalgia. skin reactions ▶Uncommon Confusion. depression. erectile dysfunction. gynaecomastia. hallucination. hepatic disorders. leucopenia. nausea. tachycardia ▶Rare or very rare Agranulocytosis. alopecia. arthralgia. atrioventricular block. fever. galactorrhoea. pancytopenia . thrombocytopenia. vasculitis eiiii F 78

Source pages 100, 101

Pregnancy

No evidence of harm; absorption from gastro- intestinal tract negligible.

Source page 100

Breast Feeding

Amount probably too small to be harmful.

Source page 100

Renal Impairment

Use with caution; aluminium is absorbed and may accumulate.

Source page 100

Dose and formulations

Extracted information for Sucralfate only.

Directions For Administration

Administration of sucralfate and enteral feeds should be separated by 1 hour and for administration by mouth, sucralfate should be given 1 hour before meals. Oral suspension blocks ﬁne- bore feeding tubes. Crushed tablets may be dispersed in water.

Source page 100

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension Tablet CAUTIONARY AND ADVISORY LABELS 5 ▶Sucralfate (imported) Sucralfate 1 gram Sulcrate 1g tablets | 100 tablet s Carafate 1g tablets | 100 tablet s Oral suspension CAUTIONARY AND ADVISORY LABELS 5 ▶Sucralfate (Non-proprietary) Sucralfate 100 mg per 1 ml Carafate 1g/10ml oral suspension sugar-free | 420 ml P s Sucralfate 200 mg per 1 ml Sucralfate 1g/5ml oral suspension sugar free sugar-free | 200 ml P £73.75 H2-RECEPTOR ANTAGONISTS H2-receptor antagonists Overview Histamine H2-receptor antagonists heal gastric and duodenal ulcers by reducing gastric acid output as a result of histamine H2-receptor blockade; they are also used to relieve symptoms of gastro-oesophageal reﬂux disease. H2-receptor antagonists should not normally be used for Zollinger-Ellison syndrome because proton pump inhibitors are more effective. Treatment with a H2-receptor antagonist has not been shown to be beneﬁcial in haematemesis and melaena, but prophylactic use reduces the frequency of bleeding from gastroduodenal erosions in hepatic coma, and possibly in other conditions requiring intensive care. H2- receptor antagonists also reduce the risk of acid aspiration in obstetric patients at delivery (Mendelson’s syndrome). H2-receptor antagonists f

Source page 100

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

2 g twice daily, dose to be taken on rising and at

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 100

Adults

First line only; read the complete Indications and dose section above.

2 g twice daily, dose to be taken on rising and at

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 100

Adults

First line only; read the complete Indications and dose section above.

1 g 6 times a day; maximum 8 g per day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 100

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

sucralfate

Reference monograph

Part of registered formulation

SUCRALFATE + OXETACAINE

Reference record: Sucralfate
Source: BNF 80 (2020–2021)
Printed source pages: 100, 101
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Sucralfate only.

Indications And Dose

Source page 100

Cautions

Source page 100

Prescribing And Dispensing Information

Flavours of oral liquid formulations may include aniseed and caramel.

Source page 100

Safety

Extracted information for Sucralfate only.

Interactions

→Appendix 1: sucralfate

Source page 100

Side Effects

Source pages 100, 101

Pregnancy

No evidence of harm; absorption from gastro- intestinal tract negligible.

Source page 100

Breast Feeding

Amount probably too small to be harmful.

Source page 100

Renal Impairment

Use with caution; aluminium is absorbed and may accumulate.

Source page 100

Dose and formulations

Extracted information for Sucralfate only.

Directions For Administration

Source page 100

Medicinal Forms

Source page 100

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

2 g twice daily, dose to be taken on rising and at

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 100

Adults

First line only; read the complete Indications and dose section above.

2 g twice daily, dose to be taken on rising and at

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 100

Adults

First line only; read the complete Indications and dose section above.

1 g 6 times a day; maximum 8 g per day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 100

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.